磷脂酰胆碱特异性磷脂酶C (PC-PLC) 是一种酶，它催化磷脂酰胆碱生成重要的次要信使磷胆碱和二酰甘油(DAG)。尽管PC-PLC已与许多病理状态的进展有关，包括癌症、动脉粥样硬化、炎症和神经元细胞死亡，但对PC-PLC的蛋白质水平的研究却相对较少。迄今为止，尚未发现表达PC-PLC的人类基因，而已解析的唯一PC-PLC蛋白质结构来自于蜡样芽孢杆菌（PC-PLCBc）。尽管如此，有证据表明PC-PLC的活性作为其原核细胞对应物的人类功能等效物。此外，已开发了PC-PLCBc的抑制剂作为潜在的治疗药物。最显著的类别包括2-氨基羟胺酸、硫代氨酸酯、N, N'-羟基脲、磷脂类似物、1,4-噁唑环内酮、吡咯[3,4-b]吲哚、吗啉基苯甲酸和单价离子。然而，许多药物化学研究缺乏它们在细胞和体内效应方面的证据，这阻碍了抑制剂向临床的进展。本综述概述了PC-PLC的病理意义，并从文献中突出当前进展和未来发展PC-PLC抑制剂的挑战。

Phosphatidylcholine-specific phospholipase C (PC-PLC) is an enzyme that catalyzes the formation of the important secondary messengers phosphocholine and diacylglycerol (DAG) from phosphatidylcholine. Although PC-PLC has been linked to the progression of many pathological conditions, including cancer, atherosclerosis, inflammation and neuronal cell death, studies of PC-PLC on the protein level have been somewhat neglected with relatively scarce data. To date, the human gene expressing PC-PLC has not yet been found, and the only protein structure of PC-PLC that has been solved was from Bacillus cereus (PC-PLCBc). Nonetheless, there is evidence for PC-PLC activity as a human functional equivalent of its prokaryotic counterpart. Additionally, inhibitors of PC-PLCBc have been developed as potential therapeutic agents. The most notable classes include 2-aminohydroxamic acids, xanthates, N,N'-hydroxyureas, phospholipid analogues, 1,4-oxazepines, pyrido[3,4-b]indoles, morpholinobenzoic acids and univalent ions. However, many medicinal chemistry studies lack evidence for their cellular and in vivo effects, which hampers the progression of the inhibitors towards the clinic. This review outlines the pathological implications of PC-PLC and highlights current progress and future challenges in the development of PC-PLC inhibitors from the literature.